Sean Khozin, MD, MPH is a physician-executive and board-certified oncologist internationally recognized for his pioneering work on advancing the use of artificial intelligence and novel data science solutions in cancer research and drug development. As Chief Executive Officer of the CEO Roundtable on Cancer and its independent AI research organization, Project Data Sphere, he leads initiatives that bridge cutting-edge technology with clinically-meaningful applications to accelerate cancer research and care.

Dr. Khozin is founder of Phyusion Bio LLC, an advisory and venture creation firm specializing in precision therapies and AI-powered solutions. His entrepreneurial track record includes co-founding Hello Health (acquired by Myca Health) and serving as CEO of CancerLinQ, where he orchestrated its strategic acquisition by ConcertAI.

His regulatory and industry expertise spans leadership roles at Johnson & Johnson/Janssen R&D as Global Head of Data Strategy and at the US FDA, where he served as founding Executive Director of INFORMED—the agency's first data science incubator—while helping establish the Oncology Center of Excellence. Earlier in his career at the National Cancer Institute, he spearheaded clinical research on molecular profiling strategies for targeted therapy development.

Dr. Khozin maintains his academic connections as a Research Affiliate at MIT and serves on multiple boards advancing the intersection of cancer research and artificial intelligence in biomedicine.